Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Atherosclerosis Reports
Erschienen in: Current Atherosclerosis Reports 2/2012

01.04.2012 | Coronary Heart Disease (J Farmer, Section Editor)

The J-Point Phenomenon in Aggressive Therapy of Hypertension: New Insights

verfasst von: Gurusher S. Panjrath, Sameer Chaudhari, Franz H. Messerli

Erschienen in: Current Atherosclerosis Reports | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

In the era of aggressive control of cardiovascular risk factors such as hypertension, the mantra of “lower is better” has taken a strong foothold. Although there is clear epidemiologic evidence that lower blood pressure improves specific organ-related outcomes, this rule does not apply to all patients and definitely not all target organs. The concept of J-curve or adverse outcomes at lower blood pressure has been proposed for more than three decades but has recently come under increasing scrutiny. Specifically, a relationship between adverse cardiovascular outcomes and low diastolic blood pressure has been observed in multiple clinical trials. In this article we review the advances in understanding of the J-curve phenomenon and include a discussion on specific populations that might be at higher risk due to the J-curve relationship.
Literatur
1.
Frank E. Deutsches Archiv Fur Klin. Vol 103; 1911.
2.
Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362(9395):1527–35.PubMedCrossRef
3.
Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease: part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 1990;335(8693):827–38.PubMedCrossRef
4.
Lewington S. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903–13.PubMedCrossRef
5.
Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA: The Journal of the American Medical Association. 2003;289(19):2560–71.CrossRef
6.
Stewart IMG. Relation of reduction in pressure to first myocardial infarction in patients receiving treatment for severe hypertension. The Lancet. 1979;313(8121):861–5.CrossRef
7.
Cruickshank J, Thorp J, Zacharias FJ. Benefits and potential harm of lowering high blood pressure. Lancet. 1987;329(8533):581–4.CrossRef
8.
Waller PC, Isles C, Lever AF, Murray GD, McInnes GT. Does therapeutic reduction of diastolic blood pressure cause death from coronary heart disease? J Hum Hypertens. 1988;2(1):7–10.PubMed
9.
Farnett L, Mulrow CD, Linn WD, Lucey CR, Tuley MR. The J-Curve phenomenon and the treatment of hypertension. JAMA: The Journal of the American Medical Association. 1991;265(4):489–95.CrossRef
10.
Chrysant S. Current status of aggressive blood pressure control. World Journal of Cardiology. 2011;3(3):65–71.PubMedCrossRef
11.
•• Messerli FH, Panjrath GS. The J-Curve between blood pressure and coronary artery disease or essential hypertension: exactly how essential? J Am Coll Cardiol. 2009;54(20):1827–34. This article is a comprehensive review of literature supporting the J-curve relationship and DBP over the past decade and discussion on the underlying pathophysiology.PubMedCrossRef
12.
Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, Hughes AD, Thurston H, O'Rourke M, CAFE Investigators, Anglo-Scandinavian Cardiac Outcomes Trial Investigators, CAFE Steering Committee and Writing Committee. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006;113(9):1213–25.
13.
Group JS. Principal results of the Japanese Trial to Assess Optimal Systolic Blood Pressure in Elderly Hypertensive Patients (JATOS). Hypertens Res. 2008;31(12):2115–27.CrossRef
14.
Ogihara T, Saruta T, Rakugi H, et al. Target blood pressure for treatment of isolated systolic hypertension in the elderly. Hypertension. August 1, 2010 2010;56(2):196–202.
15.
Oates DJ, Berlowitz DR, Glickman ME, Silliman RA, Borzecki AM. Blood pressure and survival in the oldest old. J Am Geriatr Soc. 2007;55(3):383–8.PubMedCrossRef
16.
Denardo SJ, Gong Y, Nichols WW, et al. Blood pressure and outcomes in very old hypertensive coronary artery disease patients: an INVEST Substudy. Am J Med. 2010;123(8):719–26.PubMedCrossRef
17.
Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358(18):1887–98.PubMedCrossRef
18.
de Craen AJM, Gussekloo J, Teng YKO, Macfarlane PW, Westendorp RGJ. Prevalence of five common clinical abnormalities in very elderly people: population based cross sectional study. BMJ. 2003;327(7407):131–2.PubMedCrossRef
19.
Hall W. Representation of blacks, women, and the very elderly (aged = 80) in 28 major randomized clinical trials. Ethn Dis. 1999;9:333–339.
20.
Denardo SJ, Messerli FH, Gaxiola E, et al. Coronary revascularization strategy and outcomes according to blood pressure (from the International Verapamil SR-Trandolapril Study [INVEST]). Am J Cardiol. 2010;106(4):498–503.PubMedCrossRef
21.
Messerli FH, Bangalore S, Htyte N, Ather S. Authors' Reply. Am J Cardiol. 2009;107(3):491–2.CrossRef
22.
• Bangalore S, Qin J, Sloan S, Murphy SA, Cannon CP, for the PITTTI. What is the optimal blood pressure in patients after acute coronary syndromes? Circulation 2010;122(21):2142–2151. In this trial of patients with recent acute coronary syndrome, DBP was found to be a predictor of poor prognosis. The J-curve relationship was observed with both SBP and DBP.
23.
Fagard RH, Staessen JA, Thijs L, et al. On-treatment diastolic blood pressure and prognosis in systolic hypertension. Arch Intern Med. 2007;167(17):1884–91.PubMedCrossRef
24.
Sleight P, Redon J, Verdecchia P, et al. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens. 2009;27(7):1360–9.PubMedCrossRef
25.
•• Bangalore S, Messerli FH, Wun C-C, et al. J-curve revisited: an analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) trial. European Heart Journal, 2010. This is a recent study on patients in whom the traditional cardiovascular risk factors were well controlled and demonstrated a J-curve relationship with DBP.
26.
•• Group AS. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med. 2011;364(9):818–828. This is the first large, randomized controlled trial in diabetic patients showing no additional benefit from aggressive blood pressure lowering.
27.
•• Cooper-DeHoff RM, Gong Y, Handberg EM, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA: The Journal of the American Medical Association 2010;304(1):61–68. This is a substudy of INVEST showing no additional benefit of tight control of SBP in patients with diabetes and/or CAD.
28.
Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int. 2002;61(3):1086–97.PubMedCrossRef
29.
Appel LJ, Wright JT, Greene T, et al. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med. 2010;363(10):918–29.PubMedCrossRef
30.
• Agarwal R. Blood pressure components and the risk for end-stage renal disease and death in chronic kidney disease. Clinical Journal of the American Society of Nephrology 2009;4(4):830–837. This trial showed a J-curve relationship between DBP and adverse outcomes in participants with CKD.
31.
Mandell BF. Hypertension: do not worry about the "J curve” treat the patient. Cleveland Clinic Journal of Medicine. 2011;78(2):74–4.PubMedCrossRef
32.
Bryan W. Hypertension and the "J-Curve". J Am Coll Cardiol. 2009;54(20):1835–6.CrossRef
Metadaten
Titel
The J-Point Phenomenon in Aggressive Therapy of Hypertension: New Insights
verfasst von
Gurusher S. Panjrath
Sameer Chaudhari
Franz H. Messerli
Publikationsdatum
01.04.2012
Verlag
Current Science Inc.
Erschienen in
Current Atherosclerosis Reports / Ausgabe 2/2012
Print ISSN: 1523-3804
Elektronische ISSN: 1534-6242
DOI
https://doi.org/10.1007/s11883-012-0233-4

Weitere Artikel der Ausgabe 2/2012

Current Atherosclerosis Reports 2/2012 Zur Ausgabe

Coronary Heart Disease (J Farmer, Section Editor)

Coronary Heart Disease in Young Adults

Coronary Heart Disease (J Farmer, Section Editor)

The Role of Carotid Intimal Thickness and Plaque Imaging in Risk Stratification for Coronary Heart Disease

Coronary Heart Disease (J Farmer, Section Editor)

Current Concepts of the Role of Oxidized LDL Receptors in Atherosclerosis

Coronary Heart Disease (J Farmer, Section Editor)

Effects of Ethanol Intake on Lipoproteins

Coronary Heart Disease (J Farmer, Section Editor)

The Role of Statin Therapy for Primary Prevention: What is the Evidence?

Coronary Heart Disease (J Farmer, Section Editor)

Bariatric Surgery: Effects on the Metabolic Complications of Obesity

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise